Mixed results were found for zinc , folic acid , vitamin C , and tryptophan , with nonsignificant results for inositol .
No major adverse effects were noted in the studies ( aside from minor digestive disturbance ) .
A meta- analysis of adjunctive omega-3 versus placebo revealed a significant and moderate to strong effect in favor of omega-3 .
Conversely , a meta- analysis of folic acid revealed a nonsignificant difference from placebo .
Current evidence supports adjunctive use of SAMe , methylfolate , omega-3 , and vitamin D with antidepressants to reduce depressive symptoms
OBJECTIVE There is burgeoning interest in augmentation strategies for improving inadequate response to antidepressants .
The adjunctive use of st and ardized pharmaceutical- grade nutrients , known as nutraceuticals , has the potential to modulate several neurochemical pathways implicated in depression .
While many studies have been conducted in this area , to date no specialized systematic review ( or meta- analysis ) has been conducted .
S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study
We investigated the efficacy of S-Adenosyl-L-Methionine ( SAMe ) augmentation in patients with treatment-resistant depressive disorder ( TRD ) . Thirty-three out patients with major depressive episode who failed to respond to at least 8 weeks of treatment with two adequate and stable doses of antidepressants were treated openly with fixed dose of SAMe ( 800 mg ) for 8 weeks , added to existing medication . The primary outcome measure was the change from baseline in total score on Hamilton Rating Scale for Depression ( HAM-D ) . The Clinical Global Impression of Improvement ( CGI-I ) was rated at the endpoint . Patients with a reduction of 50 % or more on HAM-D total score and a CGI-I score of 1 or 2 at endpoint were considered responders ; remission was defined as a HAM-D score ≤7 . Secondary outcome measures included the Snaith-Hamilton Pleasure Scale ( SHAPS ) and the Sheehan Disability Scale ( SDS ) . At 8 weeks , a significant decrease in HAM-D score was observed with response achieved by 60 % of the patients and remission by 36 % . Also a statistically significant reduction in SHAPS and SDS was observed . Our findings indicate that SAMe augmentation may be effective and well tolerated in stage II TRD . However , limitations of the present study must be considered and further placebo-controlled trials are needed
Mixed results were found for zinc , folic acid , vitamin C , and tryptophan , with nonsignificant results for inositol .
No major adverse effects were noted in the studies ( aside from minor digestive disturbance ) .
A meta- analysis of adjunctive omega-3 versus placebo revealed a significant and moderate to strong effect in favor of omega-3 .
Conversely , a meta- analysis of folic acid revealed a nonsignificant difference from placebo .
Current evidence supports adjunctive use of SAMe , methylfolate , omega-3 , and vitamin D with antidepressants to reduce depressive symptoms
OBJECTIVE There is burgeoning interest in augmentation strategies for improving inadequate response to antidepressants .
The adjunctive use of st and ardized pharmaceutical- grade nutrients , known as nutraceuticals , has the potential to modulate several neurochemical pathways implicated in depression .
While many studies have been conducted in this area , to date no specialized systematic review ( or meta- analysis ) has been conducted .